Business Description
Genelux Corp
NAICS : 541714
SIC : 2834
ISIN : US36870H1032
Description
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 19.64 | |||||
| Equity-to-Asset | 0.77 | |||||
| Debt-to-Equity | 0.06 | |||||
| Debt-to-EBITDA | -0.06 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 4/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -15.7 | |||||
| 3-Year EPS without NRI Growth Rate | -11.4 | |||||
| 3-Year FCF Growth Rate | -35.2 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 12.22 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 41.8 | |||||
| 9-Day RSI | 49.1 | |||||
| 14-Day RSI | 51.1 | |||||
| 3-1 Month Momentum % | -6.92 | |||||
| 6-1 Month Momentum % | 2.54 | |||||
| 12-1 Month Momentum % | 31.52 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.67 | |||||
| Quick Ratio | 4.67 | |||||
| Cash Ratio | 4.57 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -13.8 | |||||
| Shareholder Yield % | -34.81 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| FCF Margin % | -283625 | |||||
| ROE % | -103.94 | |||||
| ROA % | -80.27 | |||||
| ROIC % | -593.36 | |||||
| 3-Year ROIIC % | 134.31 | |||||
| ROC (Joel Greenblatt) % | -930.31 | |||||
| ROCE % | -99.4 | |||||
| Moat score | 3 | |||||
| Tariff score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 3.58 | |||||
| Price-to-Tangible-Book | 3.58 | |||||
| EV-to-EBIT | -2.46 | |||||
| EV-to-Forward-EBIT | -2.34 | |||||
| EV-to-EBITDA | -2.53 | |||||
| EV-to-Revenue | 9184.38 | |||||
| EV-to-Forward-Revenue | 5439.12 | |||||
| EV-to-FCF | -3.3 | |||||
| Price-to-Net-Current-Asset-Value | 3.99 | |||||
| Price-to-Net-Cash | 4.1 | |||||
| Earnings Yield (Greenblatt) % | -40.65 | |||||
| FCF Yield % | -21.25 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:GNLX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Genelux Corp Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.008 | ||
| EPS (TTM) ($) | -0.88 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 91.9 | ||
| 14-Day RSI | 51.1 | ||
| 14-Day ATR ($) | 0.22854 | ||
| 20-Day SMA ($) | 2.811 | ||
| 12-1 Month Momentum % | 31.52 | ||
| 52-Week Range ($) | 1.6 - 5.885 | ||
| Shares Outstanding (Mil) | 37.73 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Genelux Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Genelux Corp Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Genelux Corp Frequently Asked Questions
What is Genelux Corp(GNLX)'s stock price today?
The current price of GNLX is $2.83. The 52 week high of GNLX is $5.89 and 52 week low is $1.60.
When is next earnings date of Genelux Corp(GNLX)?
The next earnings date of Genelux Corp(GNLX) is 2025-08-14 Est..
Does Genelux Corp(GNLX) pay dividends? If so, how much?
Genelux Corp(GNLX) does not pay dividend.
Guru Commentaries on NAS:GNLX
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers